Organon (OGN) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
3 Feb, 2026Opening remarks and agenda
The meeting was conducted virtually to enhance inclusivity and participation, with shareholders able to vote and ask questions online.
The agenda included introductions, formal business, voting on proposals, and a Q&A session with the CEO.
All board members, executive officers, and key external representatives were present.
Shareholder proposals
A shareholder proposal was presented to require the board to accept the resignation of any director not re-elected by a majority vote, aiming to strengthen shareholder voting rights.
The board opposed the proposal, citing existing robust governance practices and recommending a vote against it.
Overview of voting outcomes
All director nominees were elected, and the advisory vote on executive compensation, amendment of the 2021 Incentive Stock Plan, and ratification of the accounting firm were approved by a majority.
The shareholder proposal on director resignation guidelines received 20.9% support and was not approved.
Latest events from Organon
- 2025 revenue fell 3% to $6.2B; 2026 outlook is flat with margin and policy headwinds.OGN
Q4 202512 Feb 2026 - Q2 revenue flat at $1.61B; guidance and cash flow targets reaffirmed despite margin declines.OGN
Q2 20242 Feb 2026 - All proposals passed, with strong revenue growth and a continued focus on women's health initiatives.OGN
AGM 202431 Jan 2026 - Revenue down 7% in Q1 2025; guidance, deleveraging, and dividend reset reaffirmed.OGN
Q1 202519 Jan 2026 - 2024 revenue rose 3% ex-FX, with margin strength and Women's Health and biosimilar growth.OGN
Q4 202419 Jan 2026 - Q2 2025 revenue down 1%, guidance raised, leverage reduction and portfolio growth on track.OGN
Q2 202519 Jan 2026 - Q3 revenue up 4–5%, net income surged to $359M, and 2024 guidance was raised.OGN
Q3 202417 Jan 2026 - Growth in NEXPLANON and VTAMA offsets LOE headwinds, supporting margin and expansion plans.OGN
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Internal investigation resolved; focus shifts to cost discipline, growth, and portfolio optimization.OGN
Piper Sandler 37th Annual Healthcare Conference3 Dec 2025